<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A number of cloned biologic factors are currently available that are candidates for therapy of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and, by extension, <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>gamma-Interferon and, to a greater extent, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor exhibit leukemic differentiative effects without the potential for stimulation of leukemic clones </plain></SENT>
<SENT sid="2" pm="."><plain>These effects may be enhanced by combinations of these with one another or with chemical inducers of differentiation such as <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> or <z:chebi fb="27" ids="27300">vitamin D</z:chebi> derivatives </plain></SENT>
<SENT sid="3" pm="."><plain>The colony-stimulating factors clearly have potent in vivo effects upon hematopoiesis </plain></SENT>
<SENT sid="4" pm="."><plain>The lineage specific factors (G- or M-CSF) may have greater differentiation induction potential and less risk of accelerating emergence of leukemic clones than the earlier acting factors (GM- or multi-CSF) </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, several potentially fruitful avenues for clinical research are currently available </plain></SENT>
</text></document>